Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging ...

Profit and revenue forecasts for 2026 well above Street view Lilly's Q4 profit and revenue exceed expectations Lilly's obesity drug Zepbound boosts sales despite price cuts Lilly's orforglipron pill ...

Hims & Hers Health began advertising a $49 Ozempic pill lookalike last week -- then stopped. Novo Nordisk charges $149 for its own Wegovy pills. Lilly charges $299 for Zepbound shots. First, on Friday ...

Eli Lilly's success rate in clinical trials was phenomenal last year. The drugmaker has made a big name for itself in diabetes and weight loss. But it's also proving innovative even beyond its core ...

As the 2026 Winter Olympics get underway in Italy this week, Eli Lilly—a partner of both Team USA and the Milan Cortina Games as a whole—is rolling out a new corporate campaign inspired by the event.

After Novo Nordisk projected yesterday that its revenue could decline by as much as 13% in 2026, its share price has plummeted by 20%. Because the Danish company attributed much of the shortfall to ...

As Eli Lilly awaits an FDA approval decision for its oral GLP-1 orforglipron, the pharma has discarded three clinical-stage drugs, including a gene therapy from its $1 billion acquisition of Prevail ...

Eli Lilly posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. The ...

Sales of Lilly's GLP-1 drugs are surging. Management issued a bullish profit forecast. Shares of Eli Lilly (NYSE: LLY) climbed over 10% on Wednesday after the medicine maker delivered a blockbuster ...

Eli Lilly is rated SELL due to lofty valuation, despite extraordinary execution and recent market leadership in GLP-1 and obesity drugs. LLY's current $950B market cap implies sustained 25% annual ...

Eli Lilly’s stock closed 10.3% higher on Wednesday after the drug giant reported triple-digit growth of Zepbound and Mounjaro, its game-changing weight-loss and Type 2 diabetes drugs. That’s the third ...

Eli Lilly is heading back to its regular Chinese collaborator Innovent Biologics with $350 million in upfront cash to collaborate on new meds for patients with cancer or immune disorders. The ...